A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. Our lead clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, we aim to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. Our management team has proven experience in gene therapy development and commercialization. We leverage this experience, our manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside.
| Metric | TTM | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | - | - | - |
| Net Income | -100M | -89M | -112M | -166M |
| EPS | $-0.33 | $-0.36 | $-0.96 | $-3.78 |
| Free Cash Flow | 0 | -82M | -77M | -109M |
| ROIC | -25.5% | -77.3% | -96.6% | -101.6% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.23 | 0.61 | 0.54 | 40.01 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -102M | -91M | -72M | -162M |
| Operating Margin | 0.0% | - | - | - |
| ROE | -45.6% | -121.9% | -148.9% | -17493.6% |
| Shares Outstanding | 274M | 248M | 116M | 187M |
| Metric | 2022 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A |
| EBIT | -162M | -72M | -91M | -102M |
| Op. Margin | N/A | N/A | N/A | 0.0% |
| Net Income | -166M | -112M | -89M | -100M |
| Net Margin | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 36M | 1.1M | 4.8M | 4.8M |
| Returns on Capital | ||||
| ROIC | -101.6% | -96.6% | -77.3% | -25.5% |
| ROE | -17493.6% | -148.9% | -121.9% | -45.6% |
| ROA | -131.5% | -64.6% | -53.6% | -31.6% |
| Cash Flow | ||||
| Op. Cash Flow | -88M | -73M | -81M | -85M |
| Free Cash Flow | -109M | -77M | -82M | 0 |
| Owner Earnings | -108M | -82M | -96M | -99M |
| CapEx | 21M | 3.9M | 374K | 0 |
| Maint. CapEx | 1.2M | 1.4M | 1.2M | 1.2M |
| Growth CapEx | 19M | 2.5M | 0 | 0 |
| D&A | 1.2M | 1.4M | 1.2M | 1.2M |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 18M | 7.9M | 13M | 13M |
| Debt Repayment | 0 | 399K | 18K | 18K |
| Balance Sheet | ||||
| Net Debt | -50M | -103M | -95M | -246M |
| Cash & Equiv. | N/A | N/A | N/A | 297M |
| Long-Term Debt | 38M | 41M | 44M | 44M |
| Debt/Equity | 40.01 | 0.54 | 0.61 | 0.23 |
| Interest Coverage | -42.8 | -14.5 | -896.7 | -896.7 |
| Equity | 949K | 75M | 72M | 219M |
| Total Assets | 126M | 173M | 160M | 317M |
| Total Liabilities | 125M | 98M | 89M | 18M |
| Intangibles | N/A | N/A | N/A | N/A |
| Retained Earnings | -401M | -513M | -602M | -602M |
| Working Capital | 34M | 113M | 116M | 116M |
| Current Assets | 96M | 150M | 142M | 142M |
| Current Liabilities | 63M | 37M | 26M | 26M |
| Per Share Data | ||||
| EPS | -3.78 | -0.96 | -0.36 | -0.33 |
| Owner EPS | -0.58 | -0.71 | -0.39 | -0.36 |
| Book Value | 0.01 | 0.64 | 0.29 | 0.80 |
| Cash Flow/Share | -0.47 | -0.63 | -0.33 | -0.36 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 187.0M | 116.2M | 248.1M | 273.9M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -14.3 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | 382.3 | 2.8 | 6.1 | 5.9 |
| Price/Sales | N/A | N/A | N/A | N/A |
| FCF Yield | -30.0% | -37.2% | -18.8% | N/A |
| Market Cap | 363M | 207M | 434M | 1.3B |
| Avg. Price | 4.39 | 1.48 | 2.32 | 4.71 |
| Year-End Price | 1.94 | 1.78 | 1.75 | 4.71 |
Taysha Gene Therapies, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Taysha Gene Therapies, Inc. (TSHA) has a 5-year average return on invested capital (ROIC) of -91.9%. This is below average and may indicate limited pricing power.
Taysha Gene Therapies, Inc. (TSHA) has a market capitalization of $1.3B. It is classified as a small-cap stock.
Taysha Gene Therapies, Inc. (TSHA) does not currently pay a regular dividend.
Taysha Gene Therapies, Inc. (TSHA) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Taysha Gene Therapies, Inc. (TSHA) generated $-82 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Taysha Gene Therapies, Inc. (TSHA) has a debt-to-equity ratio of 0.61. This indicates moderate leverage.
Taysha Gene Therapies, Inc. (TSHA) reported earnings per share (EPS) of $-0.36 in its most recent fiscal year.
Taysha Gene Therapies, Inc. (TSHA) has a return on equity (ROE) of -121.9%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 3 years of financial data for Taysha Gene Therapies, Inc. (TSHA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Taysha Gene Therapies, Inc. (TSHA) has a book value per share of $0.29, based on its most recent annual SEC filing.